Three Seasons Wealth LLC Invests $444,000 in 10x Genomics, Inc. (NASDAQ:TXG)

Three Seasons Wealth LLC purchased a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 30,948 shares of the company’s stock, valued at approximately $444,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stifel Financial Corp grew its holdings in shares of 10x Genomics by 56.2% during the third quarter. Stifel Financial Corp now owns 16,369 shares of the company’s stock worth $370,000 after purchasing an additional 5,890 shares during the last quarter. Barclays PLC grew its holdings in 10x Genomics by 11.7% during the 3rd quarter. Barclays PLC now owns 602,536 shares of the company’s stock worth $13,605,000 after acquiring an additional 63,079 shares during the last quarter. JPMorgan Chase & Co. increased its position in 10x Genomics by 355.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock valued at $8,027,000 after acquiring an additional 277,355 shares in the last quarter. Diversified Trust Co bought a new position in shares of 10x Genomics in the fourth quarter worth about $511,000. Finally, Green Alpha Advisors LLC acquired a new position in shares of 10x Genomics during the fourth quarter worth approximately $355,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares in the company, valued at approximately $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

TXG has been the subject of a number of research reports. Barclays lowered their price target on shares of 10x Genomics from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Stifel Nicolaus dropped their target price on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. UBS Group cut their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Morgan Stanley lowered their price objective on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Citigroup cut their target price on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $19.79.

10x Genomics Stock Up 3.6 %

Shares of NASDAQ TXG opened at $8.31 on Friday. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $29.37. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -5.47 and a beta of 2.01. The company’s fifty day moving average is $9.55 and its 200-day moving average is $13.19.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, research analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.